Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults

Abstract

In our population of obese but otherwise healthy individuals, obesity clearly alters the pharmacokinetics of fluconazole, which puts severely obese adults, particularly if male, at risk of suboptimal exposure, for which adjusted doses are proposed.